Phase 3 PF-08634404 PD-1×VEGF bispecific antibody plus chemo vs pembrolizumab in 1L NSCLC
Trial status
Currently Recruiting
Status as of
Got an update?- Trial ID
- NCT07222566 on ClinicalTrials.gov
- Cancer type
- Non-Small Cell Lung Cancer (NSCLC)
- Stage of research
- Registrational
- Location
- 17 locations (US including Puerto Rico, Canada, and Japan)
- Published in
- New in Oncology - Feb 24, 2026
This Phase 3, double-blind, randomized Pfizer study tests whether PF-08634404—a bispecific antibody targeting PD-1 (checkpoint inhibition to restore T-cell activity) and VEGF (anti-angiogenesis/immune–microenvironment modulation)—combined with platinum-based chemotherapy improves outcomes versus pembrolizumab (Merck’s PD-1 monoclonal antibody) plus the same chemotherapy in untreated, unresectable stage IIIB/IIIC or metastatic stage IV NSCLC. The trial is split by histology: Part 1 enrolls squamous NSCLC and Part 2 enrolls non-squamous NSCLC, with maintenance continuing as PF-08634404 or pembrolizumab (plus a chemo component in non-squamous maintenance per protocol). It focuses on patients without known actionable genomic alterations and who are not candidates for curative surgery or chemoradiotherapy—i.e., the typical “first-line metastatic” population where regimen selection hinges on histology and biomarker/genomic exclusions. The commercial/scientific angle is a head-to-head attempt to replace the widely used pembrolizumab+chemo backbone by building VEGF blockade into the same molecule as PD-1 inhibition, a class approach also being pursued by other PD-(L)1×VEGF bispecific programs. Today’s care for these patients is pembrolizumab plus platinum doublet chemotherapy (with pemetrexed commonly used in non-squamous) followed by pembrolizumab-based maintenance, while bevacizumab/anti-VEGF strategies are used more selectively depending on regimen, histology, and bleeding risk.
More on NCT07222566
-
Trial result · Jun 11, 2026
SSGJ-707 (PF-08634404) PD-1×VEGF Bispecific Delivers 67.6% ORR and 12.4-mo mPFS in 1L PD-L1+ NSCLC
More in non-small cell lung cancer
-
New trial · Nov 19, 2026 · NCT07756645
Phase 3 ABBV-1480 PD-1×VEGF bispecific antibody vs pembrolizumab in 1L sqNSCLC -
New trial · Nov 19, 2026 · NCT07393555
Phase 2 sacituzumab govitecan (TROP2 ADC) ± ivonescimab (PD-1×VEGF bispecific) in AGA+ NSCLC -
New trial · Nov 19, 2026 · NCT07899801
Phase 1a/1b zanidatamab (HER2 bispecific antibody) + zongertinib (HER2 TKI) in HER2-mutated NSCLC -
New trial · Nov 12, 2026 · NCT07874490
Phase 2 osimertinib EGFR inhibitor plus cyclosporine A calcineurin/NFAT inhibitor in EGFR-mutant NSCLC -
New trial · Nov 12, 2026 · NCT07871214
Phase 2 pumitamig PD‑L1×VEGF‑A bispecific antibody neoadjuvant platform in resectable NSCLC.
